The study was discontinued due to unfavorable interim analysis

The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis

Inclusion Criteria:

• relapsing form of MS
• screening EDSS score 0 - 5.5, inclusive
• at least one clinical relapse in the 12 months before screening
• active disease, defined by set of MRI activity criteria
• failed prior treatment with beta-interferons or glatiramer acetate

Exclusion Criteria:

• signs of silent infections, including positive tests for HIV1, HIV2 or Hepatitis B or Hepatitis C or tuberculosis
• known allergy to gadolinium-DTPA, and/or ingredients of the study drug formulation
• pre-treatment with immunosuppressive or immunomodulatory drugs prior to screening within certain time frames